A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

Plaque-Type Psoriasis Clinical Trial

Official title:

A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00852761
• Other study ID #: 114569
• Secondary ID: U0280-402
• Status: Completed
• Phase: Phase 4
• First received: February 25, 2009
• Last updated: April 19, 2012
• Start date: March 2009
• Est. completion date: August 2009

Study information

• Verified date: April 2012
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the efficacy and safety of two different forms of a topical steroid (clobetasol propionate) in patients with plaque-type psoriasis.

Description:

This study is being conducted to obtain efficacy and tolerability data for two clobetasol propionate therapies in the treatment of plaque-type psoriasis. Subjects will be randomized to only one of the two therapies for treatment throughout the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Body surface area (BSA) affected with psoriasis between 4% and 20% .

• Target lesion of at least 2 cm² on the elbow and/or knee, with a score of 2 or 3 on the Psoriasis Grading Scale for Target Lesion.

• Elbow and/or knee plaque-type psoriasis with a Psoriasis Global Assessment of mild or moderate (2 or 3).

• Definitive diagnosis of elbow and/or knee plaque-type psoriasis.

• Capable of understanding and willing to provide a signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures were performed.

• Male or female, 18 years of age or older at the time that the consent form was signed.

• Able to complete the study and comply with study instructions.

• Female subjects of childbearing potential must have had a negative pregnancy test. Sexually active women of childbearing potential participating in the study must have been using a medically acceptable form of contraception.

Exclusion Criteria:

• Use of any emollient applied to psoriasis plaques treated with the study medication during the study.

• Other serious skin disorder or any chronic medical condition that is not well controlled.

• Female subjects who are pregnant, trying to become pregnant or lactating.

• Any major illness within 30 days prior to the baseline visit.

• Received any investigational drug or treatment within 30 days of the baseline visit or who are scheduled to receive an investigational drug or treatment other than the study products during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Plaque-Type Psoriasis
• Psoriasis

Intervention

Drug:
• Olux-E Foam
Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
• Clobex lotion
Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences Department of Dermatology	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Stiefel, a GSK Company	GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale)	Number of participants who achieved a minimum 1-grade improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.	Baseline to day 15	No
Secondary	At Least 1 Grade Improvement Psoriasis Grading Scale	Number of participants who achieve a minimum one grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.; The scale is the same as used for the primary outcome (0 through 5).	Baseline, days 3 and 8	No
Secondary	At Least a 2 Grade Improvement Psoriasis Grading Scale	Number of participants who achieve a minimum two grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.; The scale is the same as used for the primary outcome (0 through 5).	Baseline, days 3, 8, 15	No
Secondary	At Least a 3 Grade Improvement Psoriasis Grading Scale	Number of participants who achieve a minimum of three grade improvement or more in their elbow and/or knee target lesion as defined by the Psoriasis Grading Scale for Target Lesion.; The scale is the same as used for the primary outcome (0 through 5).	Baseline, days 3, 8, 15	No
Secondary	At Least 1 Grade Improvement in the Psoriasis Global Assessment	Number of participants who acheive at least a 1 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.	Baseline, days 3, 8, 15	No
Secondary	At Least a 2 Grade Improvement in the Psoriasis Global Assessment	Number of participants who acheive at least a 2 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.	Baseline, days 3, 8, 15	No
Secondary	At Least a 3 Grade Improvement in the Psoriasis Global Assessment	Number of participants who acheive at least a 3 grade improvement in the Psoriasis Global Assessment. 0 = Clear; 1 = Almost Clear; 2 = Mild; 3 = Moderate; 4 = Severe.	Baseline, days 3, 8, 15	No
Secondary	At Least 1 Grade Improvement in Subject's Global Assessment	Number of participants who achieve treatment success (minimum one grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.	Baseline, days 3, 8, 15	No
Secondary	At Least a 2 Grade Improvement in Subject's Global Assessment	Number of participants who achieve treatment success (minimum two grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.	Baseline, days 3, 8, 15	No
Secondary	At Least a 3 Grade Improvement in Subject's Global Assessment	Number of participants who achieve treatment success (minimum three grade improvement or more) in their elbow and/or knee target lesion as defined by the Subject's Global Assessment. 0 = My skin is completely clear, except for residual hyperpigmentation. 1 = My psoriasis is almost clear; patchy fine scaling may be present. 2 = My psoriasis is mild, with a small amount of psoriasis. 3 = My psoriasis is moderate, between slight and definitely noticeable. 4 = My psoriasis is very noticeable. 5 = My psoriasis is severe with severe redness, thick scaling, plaques.	Baseline, days 3, 8, 15	No
Secondary	Median Change in Psoriasis Grading Scale	Median improvement in elbow and/or knee lesion using the Psoriasis Grading Scale for Target Lesion Score: 0 = No evidence of scaling, erythema, or elevation. 1 = Minimal; occasional scale, faint erythema, slight elevation. 2 = Mild; fine scales, light red color, slight elevation. 3 = Moderate; coarse scales, moderate red coloration and elevation . 4 = Marked; thick scale, bright red coloration, marked elevation. 5 = Severe; very thick tenacious scale predominates, dusky to deep red coloration, very marked elevation.	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Symptoms and Feelings	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for questions 1 and 2. Score range from 0 to 6. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Daily Activities	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for questions 3 and 4. Score range from 0 to 6. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Leisure	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for questions 5 and 6. Score range from 0 to 6. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Work and School	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for questions 7. Score range from 0 to 3. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Personal Relationships	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for questions 8 and 9. Score range from 0 to 6. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Quality of Life - Treatment	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for question 10. Score range from 0 to 3. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Total Dermatology Life Quality Index (DLQI) Score	Dermatology Quality of Life (DLQI) measures quality of life for people with skin conditions.; Sum of scores for all questions. Score range from 0 to 30. A higher score denotes a more impaired quality of life	Baseline, Days 3, 8, 15	No
Secondary	Dermatology Life Quality Index (DLQI) Categories	Number of participants who indicated one of the following for total DLQI: 0-1 No effect on the patient's life; 2-5 Small effect on the patient's life; 6-10 Moderate effect on the patient's life; 11-20 Very large effect on the patient's life.	Days 3, 8, 15	No